Every year, millions of lives are impacted by age-related diseases that rob people of their health, independence, and time with loved ones. Apollo Health Ventures exists to change this reality by building next-generation companies that extend healthy human lifespan through cutting-edge biotechnology and breakthrough science. As a transatlantic early-stage venture capital firm, the team actively co-founds and invests in transformative healthcare companies targeting age-related diseases and aging itself, leveraging deep scientific and operational expertise to turn untapped technologies into life-changing treatments.
The firm operates on a dual strategy: their Venture Lab partners with scientific experts to create new companies from the ground up, acquiring founder shares at nominal value while building top teams and conducting killer experiments to minimize risk. Simultaneously, they identify and accelerate best-in-class companies at early stages, providing access to capital, strong syndicates, and extensive networks across Europe and the United States. By enabling scientific breakthroughs in companies like Auron Therapeutics, Therini Bio, and HAYA Therapeutics, Apollo Health Ventures aims to impact human health within the next decade, proving that biotechnology is the solution for a healthier lifespan and reduced healthcare spending.